Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice

Food and Chemical Toxicology

Volumn 47, Issue 2, 2009, Pages 454-461

  Canistro, D ^a   Bonamassa, B ^a   Pozzetti, L ^a   Sapone, A ^a   Abdel Rahman, S Z ^b   Biagi, G L ^a   Paolini, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Chemoprevention; Cytochrome P450; Glutathione S transferase; Resveratrol; UDP glucuronosyl transferase

Indexed keywords

7 ETHOXYCOUMARIN DEETHYLASE; CYTOCHROME P450; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; OXYGENASE; PENTOXYRESORUFIN DEALKYLASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; RESVERATROL; TESTOSTERONE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CELL FRACTIONATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; LIVER MICROSOME; LIVER WEIGHT; LUNG; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; XENOBIOTIC METABOLISM;

ANIMALS; ANTICARCINOGENIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INJECTIONS, INTRAPERITONEAL; LIVER; LUNG; MALE; METABOLIC DETOXICATION, PHASE II; MICE; MICE, INBRED STRAINS; OXIDOREDUCTASES; STILBENES; TRANSFERASES;

MURINAE; MUS; RICE STRIPE VIRUS;

EID: 58149500695     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.11.040     Document Type: Article

References (80)

1. Ahmad A., Farhan Asad S., Singh S., and Hadi S.M. DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett. 154 (2000) 29-37
2. Aitio A. A simple and sensitive assay of 7-ethoxycoumarin demethylation. Anal. Biochem. 85 (1978) 488
3. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., and Kim A.L. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224 (2007) 274-283
4. Bailey Y.L. Techniques in Protein Chemistry (1967), Elsevier, Amsterdam pp. 340-341
5. Bairati I., Meyer F., Gélinas M., Fortin A., Nabid A., Brochet F., Mercier J.P., Têtu B., Harel F., Mâsse B., Vigneault E., Vass S., del Vecchio P., and Roy J. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J. Natl. Cancer Inst. 97 (2005) 458-481
6. Bauer C., Corsi C., and Paolini M. Stability of microsomal monooxygenases in murine liver S9 fractions derived from phenobarbital and β-naphthoflavone induced animals under various long-term conditions of storage. Teratogen. Carcin. Mut. 14 (1994) 13-22
7. Baur J.A., and Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5 (2006) 493-506
8. Berge G., Ovrebo S., Eilertsen E., Haugen A., and Mollerup S. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br. J. Cancer 91 (2004) 1380-1383
9. Boocock D.J., Faust G.E., Patel K.R., Schinas A.M., Brown V.A., Ducharme M.P., Booth T.D., Crowell J.A., Perloff M., Gescher A.J., Steward W.P., and Brenner D.E. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1246-1252
10. Bove K., Lincoln D.W., and Tsan M.F. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 291 (2002) 1001-1005
11. Box G.E.P., and Hunter W.G. Statistics for Experiments (1978), Wiley, New York pp. 80-82
12. Bruce M. Microsomal NADPH cytochrome c-reductase. Meth. Enzymol. 10 (1967) 551-553
13. Burke M.D., Thompson S., Elcombe C.R., Halpert J., Haaparant T., and Meyer R.T. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologueses: a series of substrates to distinguish between different induced cytochrome P450. Biochem. Pharmacol. 34 (1985) 3337-3345
14. Cao Z., and Li Y. Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. 489 (2004) 39-48
15. Casper R.F., Queste M., Rogers I.M., Shirota T., Jolivet A., Milgrom E., and Savouret J.F. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 56 (1999) 784-790
16. Chan W.K., and Delucchi A.B. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67 (2000) 3103-3112
17. Chang T.K., Lee W.B., and Ko H.H. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can. J. Physiol. Pharmacol. 78 (2000) 874-881
18. Chen Y., Tseng S.H., Lai H.S., and Chen W.J. Resveratrol-induced cellular apoptosis and cell cycle arrest in neuroblastoma cells and antitumor effects on neuroblastoma in mice. Surgery 136 (2004) 57-66
19. Chung W.G., and Cha Y.N. Oxidation of caffeine to theobromine and theophillyne is catalysed primarily by flavin-containing monooxygenase in liver microsomes. Biochem. Biophys. Res. Commun. 235 (1997) 685-688
20. Ciolino H.P., Daschner P.J., and Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58 (1998) 5707-5712
21. Clement M.V., Hirpara J.L., Chawdhury S.H., and Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92 (1998) 996-1002
22. Crowell J.A., Korytko P.J., Morrissey R.L., Booth T.D., and Levine B.S. Resveratrol-associated renal toxicity. Toxicol. Sci. 82 (2004) 614-619
23. Delmas D., Lançon A., Colin D., Jannin B., and Latruffe N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets 7 (2006) 423-442
24. Floreani M., Napoli E., Quintieri L., and Palatini P. Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci. 72 (2003) 2741-2750
25. Fremont L. Biological effects of resveratrol. Life Sci. 66 (2000) 663-673
26. Fulda S., and Debatim K.M. Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect. Prev. 30 (2006) 217-223
27. Habig W., Pabst M., and Jakoby W. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
28. Haworth R.S., and Avkiran M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 62 (2001) 1647-1651
29. Hebbar V., Shen G., Hu R., Kim B.R., Chen C., Korytko P.J., Crowell J.A., Levine B.S., and Kong A.N. Toxicogenomics of resveratrol in rat liver. Life Sci. 76 (2005) 2299-2314
30. Hsieh T.C., and Wu J.M. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 249 (1999) 109-115
31. Huang C., Ma W.Y., Goranson A., and Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20 (1999) 237-242
32. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
33. Kaga S., Zhan L., Matsumoto M., and Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell Cardiol. 39 (2005) 813-822
34. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur. J. Endocrinol. 138 (1998) 619-620
35. Kuroiwa Y., Nishikawa A., Kitamura Y., Kanki K., Ishii Y., Umemura T., and Hirose M. Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett. 241 (2006) 275-280
36. Lee K.W., and Lee H.J. The roles of polyphenols in cancer chemoprevention. Biofactors 26 (2006) 105-121
37. Lowry O.H., Rosenbrough H.J., Farr A.L., and Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
38. Lu R., and Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell. Physiol. 179 (1999) 297-304
39. Lubet A., Mayer M.J., Cameron J.W., Raymond W.N., Burke M., Wolf T., and Guengerich F.P. Dealkylation of pentoxyresorufin. A rapid and sensitive assay for measuring induction of cytochrome(s) P450 by phenobarbital and other xenobiotics in rat. Arch. Biochem. Biophys. 238 (1985) 43-48
40. Mackenzie P.I., and Hannien O. A sensitive kinetic assay for UDP-glucuronosyl transferase using 1-naphthol as substrate. Anal. Biochem. 109 (1980) 362-368
41. Manna S.K., Mukhopadhyay A., and Aggarwal B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164 (2000) 6509-6519
42. Matsuoka A., Furuta A., Ozaki M., Fukuhara K., and Miyata N. Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung (CHL) cell line. Mut. Res. 494 (2001) 107-113
43. Matsuoka A., Takeshita K., Furuta A., Ozaki M., Fukuhara K., and Miyata N. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mut. Res. 521 (2002) 29-35
44. Mazel P. Experiments illustrating drug metabolism in vitro. In: LaDu B.N., Mandel H.G., and Way E.L. (Eds). Fundamentals of Drug Metabolism and Drug Disposition (1971), The Williams & Wilkins Company, Baltimore, MD 546-550
45. Mgbonyebi O.P., Russo J., and Russo I.H. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12 (1998) 865-869
46. Mitchell S.H., Zhu W., and Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 59 (1999) 5892-5895
47. Mizutani K., Ikeda K., Kawai Y., and Yamori Y. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 253 (1998) 859-863
48. Morse M.A., and Stoner G.D. Cancer chemoprevention: principles and prospects. Carcinogenesis 14 (1993) 1737-1746
49. Nash T. Colorimetric estimation of formaldehyde by means of Hantzsch reaction. Biochem. J. 55 (1953) 416-421
50. Neuhouser M.L., Patterson R.E., Thornquist M.D., Omenn G.S., King I.B., and Goodman G.E. Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol. Biomarkers Prev. 12 (2003) 350-358
51. Niles R.M., Cook C.P., Meadows G.G., Fu Y.M., McLaughlin J.L., and Rankin G.O. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J. Nutr. 136 (2006) 2542-2546
52. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens Jr. F.L., Valanis B., Williams Jr. J.H., Barnhart S., Cherniack M.G., Brodkin C.A., and Hammar S. Risk factors for lung cancer and for intervention effects in CARET, the β-carotene and retinol efficacy trial. J. Natl. Cancer Inst. 88 (1996) 1550-1559
53. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes I. Evidences for its hemoprotein nature. J. Biol. Chem. 239 (1964) 2370-2378
54. Paolini M., and Nestle M. Pitfalls of enzyme-based molecular anticancer dietary manipulations: food for thought. Rev. Mutat. Res. 7704 (2003) 1-9
55. Paolini M., Barone E., Corsi C., Paganin C., and Revoltella R.P. Expression and inducibility of drug-metabolizing enzymes in novel murine liver epithelial cell lines and their ability to activate procarcinogens. Cancer Res. 51 (1991) 301-309
56. Paolini M., Pozzetti L., Sapone A., Biagi G.L., and Cantelli-Forti G. Development of basal and induced testosterone hydroxylase activity in the chicken embryo in vivo. Br. J. Pharmacol. 123 (1997) 344-350
57. Paolini M., Pozzetti L., Piazza F., Cantelli-Forti G., and Roda A. Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes. Hepatology 30 (1999) 730-739
58. Paolini M., Abdel-Rahman S.Z., Cantelli-Forti G., and Legator M.S. Chemoprevention or antichemoprevention? A salutary warning from the β-carotene experience. J. Natl. Cancer Inst. 93 (2001) 1110-1111
59. Paolini M., Sapone A., Canistro D., Antonelli M.A., and Chieco P. Diet and risk of cancer. Lancet 361 (2003) 257-258
60. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17 (2003) 1975-1985
61. Piver B., Berthou F., Dreano Y., and Lucas D. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 125 (2001) 83-91
62. Platt J., Molitor E., Doehmer J., Dogra S., and Oesch F. Genetically engineered V79 Chinese hamster cell. Expression of purified cytochrome P450 2B1 monooxygenase activity. Biochem. Toxicol. 4 (1989) 1-5
63. Pozo-Guisado E., Alvarez-Barrientos A., Mulero-Navarro S., Santiago-Josefat B., and Fernandez-Salguero P.M. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem. Pharmacol. 64 (2002) 1375-1386
64. Ragione F.D., Cucciolla V., Borriello A., Pietra V.D., Racioppi L., Soldati G., Manna C., Galletti P., and Zappia V. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem. Biophys. Res. Commun. 250 (1998) 53-58
65. Reinke L.A., and Mayer M.J. p-Nitrophenol hydroxylation. A microsomal oxidation which is highly inducible by ethanol. Drugs Metab. Disp. 13 (1985) 548-552
66. Revel A., Raanani H., Younglai E., Xu J., Rogers I., Han R., Savouret J.F., and Casper R.F. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J. Appl. Toxicol. 23 (2003) 255-261
67. Rotondo S., Rajtar G., Manarini S., Celardo A., Rotillo D., de Gaetano G., Evangelista V., and Cerletti C. Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br. J. Pharmacol. 123 (1998) 1691-1699
68. Sato M., Maulik N., and Das D.K. Cardioprotection with alcohol: role of both alcohol and polyphenolic antioxidants. Ann. NY Acad. Sci. 957 (2002) 122-135
69. Sato M., Pei R.J., Yuri T., Danbara N., Nakane Y., and Tsubura A. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett. 202 (2003) 137-145
70. Schmitt E., Lehmann L., Metzler M., and Stopper H. Hormonal and genotoxic activity of resveratrol. Toxicol. Lett. 136 (2002) 133-142
71. Siemann E.H., and Creasy L.L. Concentration of the phytoalexin resveratrol in wine. An. J. Eno. Vitic. 43 (1992) 49-52
72. Sporn M.B., and Suh N. Chemoprevention: an essential approach to controlling cancer. Nat. Rev. Cancer 2 (2002) 537-543
73. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 12 (2000) 5-11
74. Tessitore L., Davit A., Sarotto I., and Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21 (2000) 1619-1622
75. Tou J., and Urbizo C. Resveratrol inhibits the formation of phosphatidic acid and diglyceride in chemotactic peptide- or phorbol ester-stimulated human neutrophils. Cell. Signal. 13 (2001) 191-197
76. Van Der Hoeven T. Assay of hepatic microsomal testosterone hydroxylases by high-performance liquid chromatography. Anal. Biochem. 138 (1984) 57-65
77. Wadsworth T.L., and Koop D.R. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem. Pharmacol. 57 (1999) 941-949
78. Wenzel E., Soldo T., Erbersdobler H., and Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49 (2005) 482-494
79. Yu C., Shin Y.G., Kosmeder J.W., Pezzuto J.M., and van Breemen R.B. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun. Mass Spectrom. 17 (2003) 307-313
80. Ziegler C.C., Rainwater L., Whelan J., and McEntee M.F. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J. Nutr. 134 (2004) 5-10